Pathophysiological and Clinical Implications of Elevated Thyroid- Stimulating Hormone (TSH): Consequences and Management Strategies

Treatment of hypothyroidism with thyroid hormone replacement therapy (HRT) has been in use for more than a century and has demonstrated sustained clinical efficacy. Thyroid-stimulating hormone (TSH) is a central regulator of thyroid hormone synthesis and secretion through the hypothalamic–pituitary–thyroid axis. Elevated serum TSH reflects impaired thyroidal hormone output and increased pituitary feedback stimulation, most commonly due to early autoimmune thyroid dysfunction. Subclinical hypothyroidism (SCH), characterized by raised TSH with preserved circulating free thyroxine levels, represents a frequent biochemical finding in clinical endocrinology. Although often clinically silent, mild thyroid failure may exert measurable effects on lipid metabolism, vascular endothelial function, insulin sensitivity, and neurocognitive performance. In women of reproductive age, altered TSH homeostasis has important implications for fertility and pregnancy outcomes. Diagnostic evaluation requires confirmation with repeat testing and interpretation of thyroid autoimmunity to determine progression risk. Therapeutic decision-making remains individualized, balancing symptomatology, cardiovascular and metabolic risk, antibody status, and pregnancy considerations. This review integrates mechanistic insights with contemporary clinical evidence to guide rational evaluation and management of elevated TSH in routine practice.